Recent progress of SRC family kinase inhibitors as anticancer agents.
Src family of protein tyrosine kinases (SFKs) play key roles in regulating signal transduction in cellular processes. However, hyper-activated SFKs lead to uncontrolled cell proliferation and cancers. Many SFKs inhibitors were designed and synthesized as anticancer agents in the past several years and great progress has been made. Herein, some predominant examples of SFKs inhibitors recently developed are reviewed and special attentions are paid to the most important ATP binding site inhibitors.
Cao
Xin
X
Jiangsu Key Laboratory of Carcinogenesis and Intervention, Department of Medicinal Chemistry, China Pharmaceutical University, No. 24, Tongjiaxiang Rd, Nanjing 210009, Jiangsu Province, PR China.
You
Qi-Dong
QD
Li
Zhi-Yu
ZY
Wang
Xiao-Jian
XJ
Lu
Xiao-Yun
XY
Liu
Xiao-Rong
XR
Xu
Dan
D
Liu
Bao
B
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology*; D001665:Binding Sites / Q000187:drug effects; D015195:Drug Design; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D013329:Structure-Activity Relationship; D019061:src-Family Kinases / Q000037:antagonists & inhibitors*
D000970:Antineoplastic Agents; D019061:src-Family Kinases